Corvus Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
CRVS$11.37+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · Shares · Amount · Capital · Income (Loss) · Deficit · Equity | |||||||||||||||||
| Balance at December 31, 2021 | | 46,553,511 | | $5 | | $361,669 | | $1,869 | | $(266,381) | | $97,162 | |||||
| Stock-based compensation expense | | — | | | — | | | 2,692 | | | — | | | — | | | 2,692 |
| Unrealized loss on marketable securities | | — | | | — | | | — | | | (48) | | | — | | | (48) |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (2,384) | | | — | | | (2,384) |
| Net loss | | — | | | — | | | — | | | — | | | (41,307) | | | (41,307) |
| Balance at December 31, 2022 | | 46,553,511 | | $5 | | $364,361 | | $(563) | | $(307,688) | | $56,115 | |||||
| Issuance of common stock in connection with at-the-market offering, net | | 2,461,903 | | | — | | | 7,843 | | | — | | | — | | | 7,843 |
| Common stock issued on exercise of stock options | | 23,168 | | | — | | | 12 | | | — | | | — | | | 12 |
| Stock-based compensation expense | | — | | | — | | | 2,147 | | | — | | | — | | | 2,147 |
| Unrealized loss on marketable securities | | — | | | — | | | — | | | 66 | | | — | | | 66 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (470) | | | — | | | (470) |
| Net loss | | — | | | — | | | — | | | — | | | (27,029) | | | (27,029) |
| Balance at December 31, 2023 | | 49,038,582 | | $5 | | $374,363 | | $(967) | | $(334,717) | | $38,684 | |||||
| Common stock issued in connection with registered direct offering, net | | 13,512,699 | | | 1 | | | 16,404 | | | — | | | — | | | 16,405 |
| Pre-funded warrants issued in connection with registered direct offering, net | | — | | | — | | | 5,031 | | | — | | | — | | | 5,031 |
| Issuance of common stock upon exercise of common stock warrants | | 5,311,198 | | | 1 | | | 31,990 | | | — | | | — | | | 31,991 |
| Common stock issued on exercise of stock options | | 37,300 | | | — | | | 68 | | | — | | | — | | | 68 |
| Stock-based compensation expense | | — | | | — | | | 3,003 | | | — | | | — | | | 3,003 |
| Unrealized gain on marketable securities | | — | | | — | | | — | | | 65 | | | — | | | 65 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (386) | | | — | | | (386) |
| Net loss | | — | | | — | | | — | | | — | | | (62,293) | | | (62,293) |
| Balance at December 31, 2024 | | 67,899,779 | | $7 | | $430,859 | | $(1,288) | | $(397,010) | | $32,568 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.